shutterstock_1635580639_sundry_photography
Sundry Photography / Shutterstock.com
27 February 2020AmericasSarah Morgan

Genentech in $1.7bn immuno-oncology deal

California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
Big Pharma
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Asia-Pacific
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.

More on this story

Americas
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
Big Pharma
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Asia-Pacific
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.

More on this story

Americas
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
Big Pharma
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Asia-Pacific
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.